Hemolytic uremic syndrome (HUS) is a clinical disease that includes thrombotic microangiopathy, thrombocytopenia, and acute kidney damage as a triad. Hemolytic uremic syndrome is a set of illnesses with a variety of etiologies, resulting in variations in presentation, therapy, and prognosis. In recent years, improved knowledge of HUS, particularly those caused by genetic abnormalities in the alternative complement pathway, has resulted in revisions to the disease's nomenclature, categorization, and therapy. In addition to STEC-HUS, which is the most frequent cause of HUS in children, this review will present an updated categorization of the condition as well as current diagnostic and therapeutic options for complementmediated HUS. The triad of microangiopathy hemolytic anaemia, thrombocytopenia, and acute renal injury characterises hemolytic uremic syndrome (HUS). One of the most prevalent causes of acute renal failure in children is this condition. The clinical manifestations of hemolytic uremic syndrome are caused by thrombotic microangiopathy (TMA).
Journal of Renal Medicine received 29 citations as per Google Scholar report